OncoArendi Therapeutics has launched two new research programs: CHIT1 Selective in new therapeutic applications and a new program in the deubiquitinase platform (DUBs) being developed in oncology indications, the company said. These activities are in line with the plans for dynamic development and expansion of activities with new therapeutic goals for the coming years.
“Expanding our research portfolio in the field of drug discovery with new programs is a natural continuation of the development of already existing platforms, in which we have been building unique scientific and research experience for years. (…) . We can see that immuno-oncology is and will be one of the most dynamically developing areas in biotechnology, so we want to use our competences here, ”said Rafał Kamiński, member of the board and scientific director of OncoArendi Therapeutics.
A selective CHIT1 inhibitor will be developed as a potential treatment for non-alcoholic steatohepatitis (NASH) and / or for a wide range of neurological diseases.
OncoArendi Therapeutics is an innovative biotechnology company specializing in the research, development and commercialization of new drugs for the treatment of respiratory diseases and cancer. The company has been listed on the WSE main market since April 2018. In 2020, it had PLN 125 million of consolidated revenues.